CD38 and Miyoshi myopathy: This conclusion is in agreement with the only other study which directly compared these two radionuclides in a preclinical model [39], however also with two recent works depicting the development of two immuno-PET tracers using CD38-directed human antibody daratumumab and 89Zr [40] and 64Cu [41], respectively, in xenograft MM mice model.